Lakefront Biotherapeutics (GLPGF) Operating Leases (2019 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Operating Leases for 8 consecutive years, with $5.7 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Operating Leases fell 30.66% year-over-year to $5.7 million in Q1 2026; TTM through Mar 2026 was $5.7 million, a 30.66% decrease from a year earlier, with the FY2025 full-year figure at $5.9 million, down 34.33% from the prior year.
• Operating Leases was $5.7 million for Q1 2026 at Lakefront Biotherapeutics, down from $6.0 million in the prior quarter.
• Over five years, Operating Leases peaked at $20.5 million in Q1 2022 and troughed at $4.2 million in Q1 2024.
• A 5-year average of $8.9 million and a median of $8.0 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases sank 64.51% in 2023 and surged 96.5% in 2025, its largest moves.
• Over 5 years, Operating Leases stood at $15.0 million in 2022, then slumped by 64.51% to $5.3 million in 2023, then soared by 65.59% to $8.8 million in 2024, then plunged by 31.47% to $6.0 million in 2025, then retreated by 5.92% to $5.7 million in 2026.
• The last three Operating Leases figures came in at $5.7 million (Q1 2026), $6.0 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.